new money, page-12

Very disappinting result and I have lost a packet on paper due to a massive overreaction by the market.

This price, for a company with $50 million+ in the bank (+ another $20m in 30 days), EU marketing approval (30,000 patients- same size as US) and projections of sales of 50% of the pulmoz. market in Germany alone is ridiculous.

Only now are UK sales starting as hospital formularies get their act together.

France reimbursement process almost complete, Italy and Spain about to start...

Aussie sales getting going.

Even without USA market we are looking at say 10,000 cf patients @ A$10k per year in sales. $100 million in sales in a few short years.